When depression or anxiety intensifies as someone gradually reduces their antidepressant dose, it is easy for both patients and clinicians to assume the underlying mental health condition is returning. However, a recent study published in the journal Psychotherapy and Psychosomatics suggests that this sudden turn may reflect medication withdrawal rather than a true relapse of the illness.
Withdrawal occurs when a body that has adapted to a drug responds to a lower dose or complete cessation. With antidepressants, these reactions extend beyond low mood, anxiety, and agitation to include physical symptoms such as dizziness, headaches, and sensory disturbances.
'Wave-Like' Patterns Linked to Dose Changes
To clarify whether worsening symptoms during tapering stem from disease recurrence or withdrawal, a joint research team from Switzerland and Australia tracked 32 adults aged 18 to 75 in Switzerland. All participants had taken antidepressants for at least six months and had achieved symptom stability prior to initiating a planned taper. Researchers monitored symptom changes over 26 weeks, starting before the first dose reduction.
The findings revealed a direct relationship between dose cuts and symptom spikes. During active tapering periods, participants experienced heightened anxiety, low mood, and emotional withdrawal. Conversely, when dosages were held constant without further cuts, anxiety and emotional withdrawal symptoms noticeably subsided.
Crucially, emotional spikes coincided with physical withdrawal symptoms, including dizziness, tinnitus, sensory disturbances, muscle cramps, and vomiting. Based on these observations, researchers concluded that post-tapering mood slumps may be more closely tied to physiological withdrawal than to a returning mental health disorder.
Distinguishing Withdrawal From True Relapse
The researchers highlighted a key diagnostic difference: withdrawal typically follows a "wave-like" trajectory, repeatedly escalating and easing in direct response to dosage adjustments. In contrast, a true relapse of depression or an anxiety disorder tends to produce persistent, steadily worsening symptoms that do not rise and fall in step with incremental medication changes.
Recognizing this distinction is critical for patient care. The authors emphasized that physicians should refrain from concluding that long-term medication treatment is mandatory solely because symptoms emerge while tapering.
However, the authors noted limitations, particularly the small sample size of 32 participants, which prevents establishing a definitive causal relationship. The findings also should not encourage patients to modify or discontinue their medications independently. World Health Organization (WHO) guidelines recommend that individuals recovering from moderate-to-severe depression remain on treatment for at least six months after initial improvement, and that any subsequent discontinuation be conducted gradually under professional medical supervision.
